Cytosorbents Crp Stock Today
| CTSO Stock | USD 1.09 0.01 0.91% |
PerformanceModest
| Odds Of DistressHigh
|
Cytosorbents Crp is selling at 1.09 as of the 27th of February 2025; that is 0.91% down since the beginning of the trading day. The stock's open price was 1.1. Cytosorbents Crp has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 28th of January 2025 and ending today, the 27th of February 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 7th of November 2013 | Category Healthcare | Classification Health Care |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. The company has 60.93 M outstanding shares of which 1.93 M shares are currently shorted by private and institutional investors with about 4.02 trading days to cover. More on Cytosorbents Crp
Moving against Cytosorbents Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cytosorbents Stock Highlights
| President COO | Vincent MS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCytosorbents Crp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cytosorbents Crp's financial leverage. It provides some insight into what part of Cytosorbents Crp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cytosorbents Crp (CTSO) is traded on NASDAQ Exchange in USA. It is located in 305 College Road East, Princeton, NJ, United States, 08540 and employs 186 people. Cytosorbents Crp is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 67.02 M. Cytosorbents Crp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 60.93 M outstanding shares of which 1.93 M shares are currently shorted by private and institutional investors with about 4.02 trading days to cover.
Cytosorbents Crp currently holds about 30.16 M in cash with (21.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.69.
Check Cytosorbents Crp Probability Of Bankruptcy
Ownership AllocationCytosorbents Crp holds a total of 60.93 Million outstanding shares. 30% of Cytosorbents Crp outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cytosorbents Ownership Details
Cytosorbents Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-12-31 | 144.9 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 122.4 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 106.6 K | |
| Northern Trust Corp | 2024-12-31 | 91.6 K | |
| Renaissance Technologies Corp | 2024-12-31 | 88 K | |
| Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 60.6 K | |
| Kestra Advisory Services, Llc | 2024-12-31 | 55 K | |
| Engineers Gate Manager Lp | 2024-12-31 | 52.8 K | |
| Raymond James & Associates | 2024-09-30 | 50 K | |
| Avenir Corporation | 2024-12-31 | 3.1 M | |
| Skylands Capital, Llc | 2024-12-31 | 2.8 M |
Cytosorbents Crp Historical Income Statement
Cytosorbents Stock Against Markets
Cytosorbents Crp Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Robert MD | CoChairman Consultant | Profile | |
| MS MS | Pres COO | Profile | |
| Christian MD | Executive Marketing | Profile | |
| MS MBA | Senior Development | Profile | |
| Terri MBA | Vice Communications | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytosorbents Crp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Revenue Per Share | Quarterly Revenue Growth 0.066 | Return On Assets | Return On Equity |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.